HOW TO HIT THEM ALL IN ONE BLOW
|
|
- Jesse Reynolds
- 5 years ago
- Views:
Transcription
1 HOW TO HIT THEM ALL IN ONE BLOW
2 HCV
3 THE DISEASE More than 4 million Americans (1.3% of the U.S. population) and 170 million individuals in the world (3% worldwide) are infected with hepatitis C virus The prevalence of hepatitis C virus in Scandinavia is less than 0.5% of the population, whereas the prevalence in Egypt is over 20% 85% of individuals initially infected with this virus will become chronically infected Chronic hepatitis C virus infection causes an inflammation of the liver called chronic hepatitis. This condition can progress to scarring of the liver, called fibrosis, or more advanced scarring, called cirrhosis. Some patients with cirrhosis will go on to develop liver failure or the complications of cirrhosis, including liver cancer.
4 HCV GENOTYPES
5 THE GENOME
6 GENOTYPE VARIATION
7 HCV GENOTYPE DISTRIBUTION
8 HCV IS HIGHLY VARIABLE
9 GENOTYPE VARIATION de Oliveira et al., Nature 444, (14 December 2006) HIV-1 CRF02_AG (a), HCV genotype 4 (b) and HCV genotype 1 (c)
10 EPITOPE SELECTION FOR MAXIMAL STRAIN COVERAGE Use high performing Epitope predictions to predict potential epitopes for all supertypes Select top scoring peptides Use EpiSelect tool for maximal strain coverage
11 EPISELECT - GENOCOVER Top Scoring Peptides Genotype 1 Genotype 2 Genotype 3 Genotype 4 Genotype 5 Genotype 6 Select peptide with maximal coverage Select peptide with maximal coverage preferring uncovered strains Select peptide with maximal coverage preferring lowest covered strains Repeat until the desired number of peptides is selected
12 Peptides Peptide Predicted affinity (nm) Genome Coverage Genotype 1 Genotype 2 Genotype 3 Genotype 4 Genotype 5 Genotype 6 QPRGRRQPI SPRGSRPSW 43 DPRRRSRNL 66 3 RARAVRAKL TPAETTVRL 38 3 Of the 5 selected B7 peptides 2 has been verified CTL epitopes and are included in the Los Alamos database. HCV RESULTS -B7
13 POPULATION DIVERSITY
14 HLA-A*0101 HLA-A*0201 HLA-A*0301 HLA-B*0702 HLA-B*2705 HLA-B*4402 Select peptide with maximal MHC coverage Select peptide with maximal MHC coverage preferring uncovered MHCs Select peptide with maximal MHC coverage preferring lowest covered HLAs Repeat until the desired number of peptides is selected MHCCOVER
15 POPULATION DIVERSITY
16 ALLELE FREQUENCY XZ Y YZ XY XZ X X Y Z = 5/12 = 0.42 = 4/12 = 0.33 = 3/12 = 0.25
17 ALLELE COVERAGE X Z Y Y ZY XY XZ X Y Z = 4/6 = 0.66 = 3/6 = 0.5 = 3/6 = 0.5 XX Phenotypic frequency
18 FREQUENCY TO COVERAGE X i = q i + ((1 q i ) q i ) X i =2q i q 2 i Assumption: Alleles are independently distributed
19 COVERAGE OF PEPTIDE INDING TO MULTIPLE ALLELES Assumption: Independent distribution Cjk = Xj + (1-Xj) x Xk Cjk = Xj + Xk - XjXk
20 Population Coverage How to calculate
21 From allelefrequencies.net Use either allele frequency or phenotypic frequency or both Allele frequencies are re-calculated to phenotypic frequencies Use the average frequency observed within the population for the given allele
22 Calculate phenotypic frequency Allele frequency = q Phenotypic frequency = X X = 2xq - q 2
23 Your chosen alleles Allele X 1 X 1 2 X 2 3 X 3 4 X 4
24 Population coverage Uncovered = U 0 = 1 Do iteratively: U 1 = U 0 - (U 0 x X 1 ) U 2 = U 1 - (U 1 x X 2 ) U 3 = U 2 - (U 2 x X 3 ) U 4 = U 3 - (U 3 x X 4 ) Total coverage = 1 - U 4
25 HANDOUT HLA-A*0101 has a frequency of xx in the european population HLA-A*0301 has a frequency of yy in the european population What are the population coverage of each of the two allele What are the total coverage of the two alleles
26 MHC-POPCOVER Top Scoring Peptides HLA-A*0101 HLA-A*0201 HLA-A*0301 HLA-B*0702 HLA-B*2705 HLA-B*4402 Select peptide with maximal population coverage Select peptide with maximal coverage preferring uncovered MHCs with highest population coverage Select peptide with maximal coverage preferring lowest covered HLAs with highest population coverage Repeat until the desired number of peptides is selected
27 POPCOVER Genotype 1 HLA-A*0101 Genotype 2 HLA-A*0201 Genotype 3 HLA-A*0301 Genotype 4 HLA-B*0702 Genotype 5 HLA-B*2705 Genotype 6 HLA-B*4402 Select peptide with maximal population coverage and maximal genotype coverage Select peptide with maximal coverage preferring uncovered MHCs with highest population coverage and maximal genotype coverage Select peptide with maximal coverage preferring lowest covered HLAs with highest population coverage and maximal genotype coverage Repeat until the desired number of peptides is selected
28 REACHING OPTIMAL COVERAGE HCV Genotypes
Epitope discovery and Rational vaccine design Morten Nielsen
Epitope discovery and Rational vaccine design Morten Nielsen mniel@cbs.dtu.dk Bioinformatics in a nutshell List of peptides that have a given biological feature Mathematical model (neural network, hidden
More informationSelection of epitope-based vaccine targets of HCV genotype 1 of Asian origin: a systematic in silico approach
www.bioinformation.net Hypothesis Volume 8(20) Selection of epitope-based vaccine targets of HCV genotype 1 of Asian origin: a systematic in silico approach Abida Shehzadi 1 *, Shahid Ur Rehman 1, 2 &
More informationHost Genomics of HIV-1
4 th International Workshop on HIV & Aging Host Genomics of HIV-1 Paul McLaren École Polytechnique Fédérale de Lausanne - EPFL Lausanne, Switzerland paul.mclaren@epfl.ch Complex trait genetics Phenotypic
More informationVaccine Design: A Statisticans Overview
GoBack : A Statisticans Overview. Surajit Ray sray@samsi.info Surajit Ray Samsi PostDoc Seminar: Nov 2: 2004 - slide #1 The Chinese are credited with making the observation that deliberately infecting
More informationThe Immune Epitope Database Analysis Resource: MHC class I peptide binding predictions. Edita Karosiene, Ph.D.
The Immune Epitope Database Analysis Resource: MHC class I peptide binding predictions Edita Karosiene, Ph.D. edita@liai.org IEDB Workshop October 29, 2015 Outline Introduction MHC-I peptide binding prediction
More informationViral Hepatitis. WHO Regional Office for Europe July 2013
Viral Hepatitis WHO Regional Office for Europe July 2013 What is Hepatitis? Hepatitis is a viral infection that causes inflammation of the liver There are five main types of viral hepatitis: A, B, C, D,
More informationAccess to hepatitis medicines
World Hepatitis Summit November 2 nd 2017 Access to hepatitis medicines Dr Andrew Hill, PhD, Department of Translational Medicine University of Liverpool, UK 1 Changes in HCV prevalence: 2016-2017 Worldwide,
More informationHepatitis C SYMPTOMS COMPLICATIONS
Hepatitis C Hepatitis simply means "inflammation of the liver". Hepatitis C is a virus that was isolated in 1989. Since then, a tremendous amount has been learned about the virus. SYMPTOMS Hepatitis C
More informationProfiling HLA motifs by large scale peptide sequencing Agilent Innovators Tour David K. Crockett ARUP Laboratories February 10, 2009
Profiling HLA motifs by large scale peptide sequencing 2009 Agilent Innovators Tour David K. Crockett ARUP Laboratories February 10, 2009 HLA Background The human leukocyte antigen system (HLA) is the
More informationVaccine Design: A Statisticans Overview
GoBack : A Statisticans Overview. Surajit Ray sray@samsi.info Surajit Ray Samsi PostDoc Seminar: Nov 2: 2004 - slide #1 The Chinese are credited with making the observation that deliberately infecting
More informationLecture 6. Burr BIO 4353/6345 HIV/AIDS. Tetramer staining of T cells (CTL s) Andrew McMichael seminar: Background
Lecture 6 Burr BIO 4353/6345 HIV/AIDS Andrew McMichael seminar: Background Tetramer staining of T cells (CTL s) 1. Vβ 19: There are 52 T cell receptor (TCR) Vβ gene segments in germ line DNA (See following
More informationDegenerate T-cell Recognition of Peptides on MHC Molecules Creates Large Holes in the T-cell Repertoire
Degenerate T-cell Recognition of Peptides on MHC Molecules Creates Large Holes in the T-cell Repertoire Jorg J. A. Calis*, Rob J. de Boer, Can Keşmir Theoretical Biology & Bioinformatics, Utrecht University,
More information2017 UnitedHealthcare Services, Inc.
UnitedHealthcare Pharmacy Clinical Pharmacy Programs Program Number 2017 P 1146-7 Program Prior Authorization/Notification Medication Harvoni (ledipasvir/sofosbuvir) P&T Approval Date 10/2014, 2/2015,
More information/ / Please provide contact information and indicate ONE method of preferred contact for notification of the results: me at:
Please note that the patient AND physician must complete this form. All fields are mandatory and must be completed. Incomplete forms may result in your application being declined. Please retain a copy
More informationHepatitis C Cure The Invisible Epidemic
Hepatitis C Cure The Invisible Epidemic Iris House 8 Th Annual Face of AIDS Summit Hadiyah Charles Hepatitis Advocacy Manager Harm Reduction Coalition Hepatitis C Basics A virus that can cause chronic
More informationBjoern Peters La Jolla Institute for Allergy and Immunology Buenos Aires, Oct 31, 2012
www.iedb.org Bjoern Peters bpeters@liai.org La Jolla Institute for Allergy and Immunology Buenos Aires, Oct 31, 2012 Overview 1. Introduction to the IEDB 2. Application: 2009 Swine-origin influenza virus
More informationUse of BONSAI decision trees for the identification of potential MHC Class I peptide epitope motifs.
Use of BONSAI decision trees for the identification of potential MHC Class I peptide epitope motifs. C.J. SAVOIE, N. KAMIKAWAJI, T. SASAZUKI Dept. of Genetics, Medical Institute of Bioregulation, Kyushu
More informationMonitoring Hepatitis C
Monitoring Hepatitis C Section Six Monitoring Hepatitis C Screening for hepatitis C is not routinely done, so you may have to request a test from your medical provider. This usually involves an antibody
More informationNIH Consensus Conference Statement. Management of Hepatitis C. March 24-26, NIH Web site. Available at:
ABC s of Hepatitis C Treatment Today Elizabeth N. Britton, MSN, FNP-BC Hepatology Services Louisiana State University Health Sciences Center ebritt@lsuhsc.edu ANAC CONFERENCE -TUCSON NOV 2012 Hepatitis
More informationHEPATITIS C. The Facts
HEPATITIS C The Facts Your liver keeps you healthy in many ways, such as by removing toxins from your blood and transforming nutrients from food into energy. Hepatitis means inflammation of the liver.
More informationViral Hepatitis Burden and Policy Directions in the European Region of WHO
Viral Hepatitis Burden and Policy Directions in the European Region of WHO Dr Nedret Emiroglu WHO Regional Office for Europe Brussels 14-15 October 2010 Global Burden of Chronic Viral Hepatitis 2.7% all
More information6/7/17. Immune cells. Co-evolution of innate and adaptive immunity. Importance of NK cells. Cells of innate(?) immune response
Immune cells Co-evolution of innate and adaptive immunity 1 2 Importance of NK cells Cells of innate(?) immune response Patients with NK cell deficiency may lead to fatal infections and have an increased
More informationIdentification and characterization of merozoite surface protein 1 epitope
Identification and characterization of merozoite surface protein epitope Satarudra Prakash Singh,2, Bhartendu Nath Mishra 2* Amity Institute of Biotechnology, Amity University, Uttar Pradesh, Gomti Nagar,
More informationHepatitis C Strategy. About us. What is hepatitis C?
Hepatitis C Strategy About us We support people to take control of their lives and make positive changes. For fifty years we have made a difference to people who want to change their relationship with
More informationHCV elimination : lessons from Scotland
HCV elimination : lessons from Scotland Sharon Hutchinson Glasgow Caledonian University / Health Protection Scotland BHIVA Hepatology Highlights, Edinburgh, 17 th April 2018 Disclosures Honoraria from
More informationFACTS AN EDUCATIONAL SERIES BROUGHT TO YOU BY GILEAD SCIENCES
KNOW THE FACTS AN EDUCATIONAL SERIES BROUGHT TO YOU BY GILEAD SCIENCES IT S IMPORTANT TO KNOW THE FACTS ABOUT HEP C Hepatitis C (Hep C) is a virus that infects the liver. It doesn t get talked about much
More information2017 UnitedHealthcare Services, Inc.
UnitedHealthcare Pharmacy Clinical Pharmacy Programs Program Number 2017 P 2052-10 Program Prior Authorization/Medical Necessity Medication Harvoni (ledipasvir/sofosbuvir) P&T Approval Date 4/2015, 8/2015,
More informationHEPATITIS C LESSONS PART 1
What Is Hepatitis C, How Does It Spread and What Are the Symptoms? PURPOSE To provide people in your community some basic facts about hepatitis C, and to educate them about the liver in general; to teach
More informationCytotoxicity assays. Rory D. de Vries, PhD 1. Viroscience lab, Erasmus MC, Rotterdam, the Netherlands
Cytotoxicity assays Rory D. de Vries, PhD 1 1 Viroscience lab, Erasmus MC, Rotterdam, the Netherlands Anti-influenza immunity Humoral / CD4+ / CD8+ / NK? Function of CTL Elimination of virus-infected cells?
More informationGlecaprevir-Pibrentasvir in HCV GT 1 or 4 & Prior DAA Treatment MAGELLAN-1 (Part 2)
Phase 3 Treatment-Experienced in HCV GT 1 or 4 & Prior DAA Treatment MAGELLAN-1 (Part 2) in HCV GT 1 or 4 & Prior DAA Treatment MAGELLAN-1 (Part 2): Study Features MAGELLAN-1 (Part 2) Trial Design: Randomized,
More informationHIV Drug Resistance. Together, we can change the course of the HIV epidemic one woman at a time.
HIV Drug Resistance Together, we can change the course of the HIV epidemic one woman at a time. #onewomanatatime #thewellproject What Is Resistance? HIV drugs are designed to keep the amount of HIV virus
More informationEpitope discovery. Using predicted MHC binding CENTER FOR BIOLOGICAL SEQUENCE ANALYSIS
Epitope discovery Using predicted MHC binding SARS corona virus The 2003 outbreak The disease Lung Pathology Inflammatory exudation in alveoli and interstitial spaces Monocytic and lymphocytic infiltration
More informationIn silico methods for rational design of vaccine and immunotherapeutics
In silico methods for rational design of vaccine and immunotherapeutics Morten Nielsen, CBS, Department of Systems Biology, DTU and Instituto de Investigaciones Biotecnológicas, Universidad de San Martín,
More informationEarly History of Vaccination Vaccines
6/23/13 Early History of Vaccination Vaccines The tradition of vaccination may have originated in India in AD 1000 Pioneered India and China in the 17th Powdered scabs from people infected with smallpox
More informationCalculate the percentage of cytosine for the beetle. (2)
Questions Q1. (i) Figure 10 shows the percentages of bases for three organisms. Calculate the percentage of cytosine for the beetle.... % (ii) Explain why the information given about the Ebola virus indicates
More informationHepatitis C (Hep C) By Joshua Rollins. Transmission/Reservoirs
Hepatitis C (Hep C) By Joshua Rollins Etiological Agent: Hepatitis C virus (HCV) Transmission/Reservoirs Reservoir: Human The infection stems from the Hepatitis C virus (HCV), which is Blood borne pathogen
More informationPredicting the Impact of a Nonsterilizing Vaccine against Human Immunodeficiency Virus
JOURNAL OF VIROLOGY, Oct. 2004, p. 11340 11351 Vol. 78, No. 20 0022-538X/04/$08.00 0 DOI: 10.1128/JVI.78.20.11340 11351.2004 Copyright 2004, American Society for Microbiology. All Rights Reserved. Predicting
More informationHepatitis C in Australia:
Hepatitis C in Australia: Epidemiology and Clinical Presentation (and a bit of virology ) A/Prof Mark Douglas Hepatitis C - Distribution Te and Jensen 2010 Clin Liver Dis Hepatitis C Epidemiology Estimated
More informationUNIT 3 GENETICS LESSON #30: TRAITS, GENES, & ALLELES. Many things come in many forms. Give me an example of something that comes in many forms.
UNIT 3 GENETICS LESSON #30: TRAITS, GENES, & ALLELES Many things come in many forms. Give me an example of something that comes in many forms. Genes, too, come in many forms. Main Idea #1 The same gene
More informationTransmission of HCV in the United States (CDC estimate)
Transmission of HCV in the United States (CDC estimate) Past and Future US Incidence and Prevalence of HCV Infection Decline among IDUs Overall incidence Overall prevalence Infected 20+ years Armstrong
More informationDIAGNOSIS AN EDUCATIONAL SERIES BROUGHT TO YOU BY GILEAD SCIENCES
UNDERSTANDING YOUR DIAGNOSIS AN EDUCATIONAL SERIES BROUGHT TO YOU BY GILEAD SCIENCES UNDERSTANDING YOUR HEP C DIAGNOSIS LEARN MORE ABOUT HEP C If you ve been diagnosed with chronic (long-lasting) hepatitis
More informationHepatitis C: Get the Facts. a workbook
Hepatitis C: Get the Facts a workbook Inspired by and Dedicated to: the OASIS Volunteer Staff TABLE OF CONTENTS 1 What is hepatitis? 3 What does the liver do? 5 Where is the liver located? 7 What is cirrhosis?
More informationT cell Vaccine Strategies for HIV, the Virus. With a Thousand Faces
JVI Accepts, published online ahead of print on 13 May 2009 J. Virol. doi:10.1128/jvi.00114-09 Copyright 2009, American Society for Microbiology and/or the Listed Authors/Institutions. All Rights Reserved.
More informationAntigen Presentation to T lymphocytes
Antigen Presentation to T lymphocytes Immunology 441 Lectures 6 & 7 Chapter 6 October 10 & 12, 2016 Jessica Hamerman jhamerman@benaroyaresearch.org Office hours by arrangement Antigen processing: How are
More informationDetection and significance of PD-1.3 SNP (rs ) and IL28B SNP (rs ) in patients with current or past hepatitis B virus (HBV) infection
Detection and significance of PD-1.3 SNP (rs11568821) and IL28B SNP (rs12979860) in patients with current or past hepatitis B virus (HBV) infection Asterios Saitis 1, Nikolaos K. Gatselis 1, Kalliopi Azariadi
More informationLecture 11. Immunology and disease: parasite antigenic diversity
Lecture 11 Immunology and disease: parasite antigenic diversity RNAi interference video and tutorial (you are responsible for this material, so check it out.) http://www.pbs.org/wgbh/nova/sciencenow/3210/02.html
More informationHow HIV Causes Disease Prof. Bruce D. Walker
How HIV Causes Disease Howard Hughes Medical Institute Massachusetts General Hospital Harvard Medical School 1 The global AIDS crisis 60 million infections 20 million deaths 2 3 The screen versions of
More informationWorldwide Causes of HCC
Approach to HCV Treatment in Patients with HCC JORGE L. HERRERA, MD, MACG UNIVERSITY OF SOUTH ALABAMA COLLEGE OF MEDICINE Worldwide Causes of HCC 60% 50% 40% 54% 30% 20% 10% 31% 15% 0% Hepatitis B Hepatitis
More informationHepatitis C Basics. Michael Bailey Director of Programming, CATIE. Mary Choy Regional Health Education Coordinator, CATIE
Hepatitis C Basics Michael Bailey Director of Programming, CATIE Mary Choy Regional Health Education Coordinator, CATIE CATIE Our History Learning Objectives 1) To learn about the basics of hepatitis C
More informationCURING HEPATITIS C IN GENERAL PRACTICE: THE FIRST 60 DAYS
CURING HEPATITIS C IN GENERAL PRACTICE: THE FIRST 60 DAYS Baker D 1,2, McMurchie M 1, Rodgers C 1, Farr V 1, Williams M 1 1 East Sydney Doctors, 2 Australasian Society for HIV Medicine 1 Disclosures Advisory
More informationPegylated Interferons and Ribavirins
Pegylated Interferons and Ribavirins Goal(s): Cover drugs only for those clients where there is evidence of effectiveness and safety Length of Authorization: 16 weeks plus 12-36 additional weeks or 12
More informationPersistent Infections
Persistent Infections Lecture 17 Biology 3310/4310 Virology Spring 2017 Paralyze resistance with persistence WOODY HAYES Acute vs persistent infections Acute infection - rapid and self-limiting Persistent
More informationModule 1 Introduction of hepatitis
Module 1 Introduction of hepatitis 1 Training Objectives At the end of the module, trainees will be able to ; Demonstrate improved knowledge of the global epidemiology of the viral hepatitis Understand
More informationImmunotherapy for HCC
Immunotherapy for HCC Jack R. Wands, MD Jeffrey and Kimberly Greenberg - Artemis and Martha Joukowsky, Professor in Gastroenterology and Professor of Medical Sciences, Director, Division of Gastroenterology
More informationNHIVNA Pre-conference Study Day Current Issues in HIV, Hepatitis and other Blood-borne Viruses In collaboration with BASLNF
NHIVNA Pre-conference Study Day Current Issues in HIV, Hepatitis and other Blood-borne Viruses In collaboration with BASLNF Royal Armouries International, Leeds 17 June 2015 17 th Annual Conference of
More informationInfectious Diseases. Colin R. Howard ( 郝高林 ) Royal Veterinary College University of London ( 伦敦大学皇家兽医学院 )
Infectious Diseases Colin R. Howard ( 郝高林 ) Royal Veterinary College University of London ( 伦敦大学皇家兽医学院 ) The Challenge of Infectious Disease Infectious disease represents the greatest challenge to mankind
More informationDiscovery of Potent, Highly Selective, Broad Spectrum Antivirals
Discovery of Potent, Highly Selective, Broad Spectrum Antivirals Fred Hutch/Merck Infectious Disease Summit May 10, 2018 Sam Lee, Ph.D. 1 Forward Looking Statements This presentation contains forward-looking
More informationGlobal Reporting System for Hepatitis (GRSH) An introduction. WHO Global Hepatitis Programme
Global Reporting System for Hepatitis (GRSH) An introduction WHO Global Hepatitis Programme 2018 Objectives 1. Explain the role of the new reporting system 2. Outline the reporting required from countries
More informationTREATMENT OF RECENTLY ACQUIRED HEPATITIS C VIRUS INFECTION (ATAHC II)
TREATMENT OF RECENTLY ACQUIRED HEPATITIS C VIRUS INFECTION (ATAHC II) A national study to find the best treatment strategy for people with recently acquired hepatitis C infection. introduction This information
More information2017 United Healthcare Services, Inc.
UnitedHealthcare Pharmacy Clinical Pharmacy Programs Program Number 2017 P 2055-10 Program Prior Authorization/Medical Necessity Medication Olysio (simeprevir) P&T Approval Date 4/2015, 11/2015, 8/2016,
More informationHEPATITIS ELIMINATION IN SUB-SAHARAN AFRICA: WHAT WILL IT TAKE?
HEPATITIS ELIMINATION IN SUB-SAHARAN AFRICA: WHAT WILL IT TAKE? Ganiyat Kikelomo OYELEKE FMCP Hepatologist & Gastroenterologist Lagos University Teaching Hospital, Nigeria. INTEREST 2018, KIGALI CONFERENCE
More informationExpress Scripts, Inc. monograph dated 5/25/2011; selected revision 6/1/2011
BENEFIT DESCRIPTION AND LIMITATIONS OF COVERAGE ITEM: PRODUCT LINES: COVERED UNDER: DESCRIPTION: CPT/HCPCS Code: Company Supplying: Setting: Coverage Criteria: Approval Period: Victrelis (boceprevir capsules)
More informationTreatment and Access to Drugs
Treatment and Access to Drugs Presenter: Co-leads: Peter Beyer & Philippa Easterbrook WHO Regional Advisor for South East Asia (SEARO): Razia Narayan Pendse Session Objectives By the end of this session,
More informationHepatitis C Management and Treatment
Hepatitis C Management and Treatment Kaya Süer Near East University Faculty of Medicine Infectious Diseases and Clinical Microbiology 1 Discovery of Hepatitis C Key facts Hepatitis C: the virus can cause
More informationT Cell Differentiation
T Cell Differentiation Ned Braunstein, MD MHC control of Immune Responsiveness: Concept Whether or not an individual makes an immune response to a particular antigen depends on what MHC alleles an individual
More informationThe Major Histocompatibility Complex (MHC)
The Major Histocompatibility Complex (MHC) An introduction to adaptive immune system before we discuss MHC B cells The main cells of adaptive immune system are: -B cells -T cells B cells: Recognize antigens
More informationEpitope Specific CD8 + T Cell Responses Predict Spontaneous Control of HIV Replication
Epitope Specific CD8 + T Cell Responses Predict Spontaneous Control of HIV Replication Florencia Pereyra, MD Partners AIDS Research Center Harvard Medical School Boston, MA Background HIV -1 elicits HLA
More informationIMMUNOINFORMATICS: Bioinformatics Challenges in Immunology
Bioinformatics 1 -- Lecture 22 IMMUNOINFORMATICS: Bioinformatics Challenges in Immunology Most slides courtesy of Julia Ponomarenko, San Diego Supercomputer Center or Oliver Kohlbacher, WSI/ZBIT, Eberhard-Karls-
More informationEC CERTIFICATE. National Institute for Biological Standards and Control (NIBSC) Blanche Lane South Mimms Potters Bar Hertfordshire EN6 3QG UK
National Institute for Biological Standards and Control (NIBSC) EC Certificate - Full Quality Assurance System Approval Certificate Annex IV (excluding sections 4 and 6) of Council Directive 98/79/EC on
More informationTolerance vs. Resistance of infectious diseases. Lea Mösch& Hanna Schiff
Tolerance vs. Resistance of infectious diseases Lea Mösch& Hanna Schiff Introduction Definitions: Tolerance: the ability to limit the disease severity induced by a given parasite burden Resistance: the
More informationMarch XX, Washington, DC Washington, DC Washington, DC Washington, DC 20515
March XX, 2017 The Honorable Thad Cochran The Honorable Patrick Leahy Chairman Vice Chairman United States Senate United States Senate Washington, DC 20510 Washington, DC 20510 The Honorable Rodney Frelinghuysen
More informationVirion Genome Genes and proteins Viruses and hosts Diseases Distinctive characteristics
Hepadnaviruses Virion Genome Genes and proteins Viruses and hosts Diseases Distinctive characteristics Hepatitis viruses A group of unrelated pathogens termed hepatitis viruses cause the vast majority
More informationWhat is Hepatitis C Virus (HCV)?
HEPATITIS C VIRUS (HCV) What is Hepatitis C Virus (HCV)? Hepatitis is an inflammation (swelling or tenderness) of the liver. Hepatitis C virus (HCV) is the most common form of viral hepatitis and usually
More informationOriginally published as:
Originally published as: Ratsch, B.A., Bock, C.-T. Viral evolution in chronic hepatitis B: A branched way to HBeAg seroconversion and disease progression? (2013) Gut, 62 (9), pp. 1242-1243. DOI: 10.1136/gutjnl-2012-303681
More informationHepatitis C treatment for people who inject drugs: are directacting antivirals cost-effective?
Hepatitis C treatment for people who inject drugs: are directacting antivirals cost-effective? Daniëla K. van Santen, Anneke S. de Vos, Amy Matser, Sophie B. Willemse, Karen Lindenburg, Mirjam E.E. Kretzschmar,
More informationDiagnosis and monitoring of hepatitis C (HCV) in Morocco Current Status and strategies for universal access
Diagnosis and monitoring of hepatitis C (HCV) in Morocco Current Status and strategies for universal access Benchmarking HCV diagnostics, fibrosis evaluation, and treatment monitoring Pauline Londeix,
More informationHD1 (FLU) HD2 (EBV) HD2 (FLU)
ramer staining + anti-pe beads ramer staining a HD1 (FLU) HD2 (EBV) HD2 (FLU).73.11.56.46.24 1.12 b CD127 + c CD127 + d CD127 - e CD127 - PD1 - PD1 + PD1 + PD1-1 1 1 1 %CD127 + PD1-8 6 4 2 + anti-pe %CD127
More informationViral Hepatitis B and C in North African Countries
Viral Hepatitis B and C in North African Countries Prevalence, Risk factors and How to prevent Prof. Ossama Rasslan President, ESIC ICAN, Vice-Chair ICAN 2014, Harare, Zimbabwe, Nov 3rd 5th Overview Viral
More informationHepatitis. Dr. Mohamed. A. Mahdi 5/2/2019. Mob:
Hepatitis Dr. Mohamed. A. Mahdi Mob: 0123002800 5/2/2019 Hepatitis Hepatitis means the inflammation of the liver. May cause by viruses or bacteria, parasites, radiation, drugs, chemical and toxins (alcohol).
More informationLIVING WITH HEPATITIS B
LIVING WITH HEPATITIS B Welcome What is hep B? Hepatitis B (or hep B) is a serious liver disease that affects millions of people across the world. This brochure is here to help you better understand hep
More informationCriteria for Indiana Medicaid Hepatitis C Agents
Prepared for State of Indiana by OptumRx EXECUTIVE SUMMARY Purpose: Promote prudent prescribing of Setting & Population: All members Type of Criteria: Increased Risk of ADE Non-Preferred Agent Appropriate
More informationDIRECT IDENTIFICATION OF NEO-EPITOPES IN TUMOR TISSUE
DIRECT IDENTIFICATION OF NEO-EPITOPES IN TUMOR TISSUE Eustache Paramithiotis PhD Vice President, Biomarker Discovery & Diagnostics 17 March 2016 PEPTIDE PRESENTATION BY MHC MHC I Antigen presentation by
More informationSeverity and Mortality Prediction in Chronic Liver Disease using Child PUGH and MELD scales
International Journal of Advanced Biotechnology and Research (IJABR) ISSN 0976-2612, Online ISSN 2278 599X, Vol-10, Issue-1, 2019, pp519-524 http://www.bipublication.com Research Article Severity and Mortality
More informationChronic Hepatitis C. Risk Factors
Chronic Hepatitis C The hepatitis C virus is one of the most important causes of chronic liver disease in the United States. Almost 4 million Americans or 1.8 percent of the U.S. population have an antibody
More information14.1 Human Chromosomes pg
14.1 Human Chromosomes pg. 392-397 Lesson Objectives Identify the types of human chromosomes in a karotype. Describe the patterns of the inheritance of human traits. Explain how pedigrees are used to study
More informationGeneral Statement for Drugs for the Treatment of Hepatitis C
General Statement for Drugs for the Treatment of Hepatitis C Use the following criteria to determine patient eligibility for subsidisation under the PBS for hepatitis C treating agents. By writing a PBS
More informationTreatment of Hepatitis C in HIV-Coinfected Patients. Vincent Soriano Department of Infectious Diseases Hospital Carlos III Madrid, Spain
Treatment of Hepatitis C in HIV-Coinfected Patients Vincent Soriano Department of Infectious Diseases Hospital Carlos III Madrid, Spain Estimated no. of persons infected with HIV and hepatitis viruses
More informationSwiss Summary of the Risk Management Plan (RMP) for. Vosevi, film-coated tablets
Swiss Summary of the Management Plan (RMP) for, film-coated tablets (Sofosbuvir/Velpatasvir/Voxilaprevir Fixed-Dose Combination) 400mg/100mg/100mg Version 1.0 (February 2018) final Based on EU RMP version
More informationGeo-epidemiology of Hepatitis C in Northeast Indiana
Geo-epidemiology of Hepatitis C in Northeast Indiana Shori Gerardot, Ashley Cross, Atit Patel, Kassidy Beck MS, Scott M. Stienecker MD, and Teresa A. Beam PhD Hepatitis C (HCV) ~180 million worldwide ~2.7-3.9
More informationAutoimmune Hepatitis Events Easl
Autoimmune Hepatitis Events Easl 1 / 6 2 / 6 3 / 6 Autoimmune Hepatitis Events Easl INTRODUCTION. Autoimmune hepatitis is a chronic, inflammatory disease of the liver that is characterized by circulating
More informationSummary of Key Points. WHO Position Paper on Vaccines against Hepatitis B, July 2017
Summary of Key Points WHO Position Paper on Vaccines against Hepatitis B, July 2017 1 Background l HBV is transmitted by exposure of mucosal membranes or non-intact skin to infected blood, saliva, semen
More informationHarvoni. Harvoni (ledipasvir & sofosbuvir) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: Harvoni Page: 1 of 7 Last Review Date: June 19, 2015 Harvoni Description Harvoni (ledipasvir &
More informationForward Looking Statements
Antiviral Therapies Forward Looking Statements This presentation contains forward-looking statements, including the timing of our drug development programs. Risks include delays in manufacturing created
More informationYou have been diagnosed with chronic hepatitis C. I I
You have been diagnosed with chronic hepatitis C I I Prevalence Estimated 130-210 million people currently infected with hepatitis C. Estimated 50,000 people in New Zealand infected with chronic hepatitis
More informationSummary of the risk management plan (RMP) for Viekirax (ombitasvir / paritaprevir / ritonavir)
EMA/775985/2014 Summary of the risk management plan (RMP) for Viekirax (ombitasvir / paritaprevir / ritonavir) This is a summary of the risk management plan (RMP) for Viekirax, which details the measures
More informationViral Hepatitis. Dr Melissa Haines Gastroenterologist Waikato Hospital
Viral Hepatitis Dr Melissa Haines Gastroenterologist Waikato Hospital Viral Hepatitis HAV HBV HCV HDV HEV Other viral: CMV, EBV, HSV Unknown Hepatitis A Hepatitis A Transmitted via the faecal-oral route
More informationHepatitis C in Disclosures
Hepatitis C in 2018 Sandeep Mukherjee, MD CHI Health and Creighton University Medical Center Division of Gastroenterology Grant support: Abbvie Disclosures Speaker: Abbvie, Gilead, Merck Section editor
More informationSummary of the risk management plan (RMP) for Olysio (simeprevir)
EMA/191406/2014 Summary of the risk management plan (RMP) for Olysio (simeprevir) This is a summary of the risk management plan (RMP) for Olysio, which details the measures to be taken in order to ensure
More informationDaklinza Sovaldi. Daklinza (daclatasvir) and Sovaldi (sofosbuvir) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: Daklinza Sovaldi Page: 1 of 4 Last Review Date: September 18, 2015 Daklinza Sovaldi Description
More informationWelcome to the Hepatitis C Education Class
Welcome to the Hepatitis C Education Class Topics of the Class Your liver Types of hepatitis How hepatitis C is spread How to protect your liver Treatment for hepatitis C What is the Liver? Makes chemicals
More information